Ribociclib Addition May Benefit Women With Advanced HR-Positive Breast Cancer

The MONALEESA-7 trial tested the combination of ribociclib with endocrine therapy in premenopausal women with advanced HR-positive/HER2-negative breast cancer.

Source: CancerNetwork - June 1, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news